

27 February 2024

PUBLICATION OF SUPPLEMENT TO BASE PROSPECTUS

NOT FOR DISTRIBUTION TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED) OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS OR INTO ANY OTHER JURISDICTION OR TO ANY OTHER PERSON WHERE OR TO WHOM IT IS UNLAWFUL TO DISTRIBUTE THIS DOCUMENT.

Diageo plc (as issuer and guarantor), Diageo Finance plc (as issuer) and Diageo Capital B.V. (as issuer) announce that, regarding their programme for the issuance of debt instruments (the "**Programme**"), they have published a supplement (the "**Supplement**") to the base prospectus dated 17 August 2023 in respect of the Programme. The Supplement was approved by the Financial Conduct Authority ("**FCA**") on 27 February 2024 and is available for viewing here:

Supplement: http://www.rns-pdf.londonstockexchange.com/rns/6571E 1-2024-2-27.pdf

Interim Results: http://www.rns-pdf.londonstockexchange.com/rns/6571E 2-2024-2-27.pdf

A copy of the Supplement has been submitted to the National Storage Mechanism ("**NSM**") and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

ENDSENDS

For further information please contact:

Investor relations:

Durga Doraisamy +44 (0) 7902 126 906 Andrew Ryan +44 (0) 7803 854 842 Brian Shipman +1 (0) 917 710 3007

investor.relations@diageo.com

Media relations:

Clare Cavana +44 (0) 7751 742 072 Isabel Batchelor +44 (0) 7731 988 857 press@diageo.com

DISCLAIMER – INTENDED ADDRESSEES

The notes and the guarantee described in the base prospectus (as supplemented) (the "Base Prospectus") have not been and will not be registered under the United States Securities Act of 1933, as amended, or any relevant securities law of any state of the United States and are subject to U.S. tax law requirements. Subject to certain exceptions, notes issued under the Programme may not be offered, sold or delivered within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions permitted by U.S tax regulations.

The Base Prospectus does not constitute an offer to sell or the solicitation of an offer to buy any notes in any jurisdiction to any person to whom it is unlawful to make the offer or solicitation in

such jurisdiction. The distribution of the Base Prospectus and the offer or sale of notes under the Programme may be restricted by law in certain jurisdictions.

Persons into whose possession the Base Prospectus or any notes issued under the Programme may come must inform themselves about, and observe, any such restrictions on the distribution of the Base Prospectus and the offering and sale of notes. In particular, please note that the information contained in this announcement may be addressed to and/or targeted at persons who are residents of particular countries only and is not intended for use and should not be relied upon by any person outside these countries.

About Diageo

Diageo is a global leader in beverage alcohol with an outstanding collection of brands across spirits and beer. These brands include Johnnie Walker, Crown Royal, J&B, Buchanan's whiskies, Smirnoff, Cîroc and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Tanqueray and Guinness.

Diageo is a global company, and our products are sold in nearly 180 countries around the world. The company is listed on both the London Stock Exchange (DGE) and the New York Stock Exchange (DEO). For more information about Diageo, our people, our brands, and performance, visit us at www.diageo.com. Visit Diageo's global responsible drinking resource, www.DRINKiQ.com for information, initiatives, and ways to share best practice.

Celebrating life, every day, everywhere.

Diageo plc

LEI: 213800ZVIELEA55JMJ32

Diageo Finance plc

LEI: BPF79TJMIH3DK8XCKI50

Diageo Capital B.V.

LEI: 213800YHFC48VOL6JY40

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.